Drugs / recombinant interleukin-21
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00601861 | Feb → Jun 2008 | cancer, melanoma | Novo Nordisk A/S | Terminated | No outcome recorded |
| Phase 2 | NCT00523380 | Oct 2007 → Jan 2009 | ovarian cancer | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT00617253 | Jul 2007 → Jun 2008 | renal cell carcinoma | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant interleukin-21 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00601861 ↗ |
| Known as | NN028, rIL-21 | “NN028, rIL-21” NCT00617253 ↗ |
| Modality | Protein / enzyme biologic | “recombinant interleukin-21” NCT00523380 ↗ |
| Route | Intravenous | “Administered i.v. in treatment cycles of 28 days.” NCT00523380 ↗ |